Pluvicto TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: lutetium (177-lu) vipivotide tetraxetan
Pack: Pluvicto 1000 MBq/mL injection, 1 mL vial
Brand name
(ARTG)
: PLUVICTO lutetium (177Lu) vipivotide tetraxetan 1000 MBq/mL solution for injection vialDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
PLUVICTO is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Injection, solution
- Intravenous
- Clear, colourless to slightly yellow solution, free from visible particles
Storage conditions
(ARTG)
- Store below 30 degrees Celsius
- Do not Freeze
- Store in Original Container
- Shelf lifetime is 5 Days.
Do I need a prescription ?
(ARTG)
We are unable to tell you if you need a prescription for these medicines. You can ask your pharmacist. This medicine is
- 1 vial pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient lutetium (177-lu) vipivotide tetraxetan
This medicine is not considered safe during pregnancy. You should discuss this medicine with your doctor or pharmacist. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
